The market is bleeding, but may be you know this quote:
"Bull markets are born on pessimism, grow on skepticism, mature on optimism, and die on euphoria" - Sir John Templeton
So the actual question is, where are we right now? I guess "Euphoria" is actually over and we are on our steady way down to realistic valuations.
Let's talk facts: As of March 31, 2022,...
Statera Biopharma and Immune Therapeutics Inc. Announce Strategic Agreement for Rights to Low Dose Naltrexone. Potential indication payments will include asthma, multiple sclerosis, HIV and chemotherapy. In aggregate, this transaction has the ability to generate over $400 million in non-dilutive payments to Statera.
NLS Pharmaceutics Announces Patent Issuance in the United States for its Mazindol Extended-Release Formulation
Key patent now granted in major markets including the U.S., Europe, Canada & South Korea
Patent claims cover use of the Company's lead product candidate, Quilience® (mazindol ER) in both attention deficit hyperactivity disorder (ADHD) &...
Genprex Receives U.S. FDA Fast Track Designation for REQORSA™️ Immunogene Therapy in Combination With Keytruda®️ for the Treatment of Non-Small Cell Lung Cancer
Second FDA Fast Track Designation Further Validates the Potential of REQORSA
AUSTIN, Texas, January 03, 2022--(BUSINESS WIRE)--Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage...
- $19M mkt cap / 11M float
- $28.4M cash eq.
- $17.1M Q3 revenue / $7M adjusted EBITDA
- Options at $3.27
- Warrants at $3.53
- Enterprise value (as of Sep 30, 2021): $103.8M!!
- Canadian Commercial business is focused on Pain, Neurology, Allergy, And Dermatology therapeutics.
- 17 Global Distribution Partners across 31 Countries.
- Over 100 global patents and...
ENVB has put up a fight at the 786 fib level for months. While it broke above and held briefly...guess where it's back to now. If you guessed the 786 fib level, you're right. But will that change this week considering what's happening?
If you’ve followed the trend in “alternative” biotech stocks, Enveric could have been one that you came across recently. That’s...
ADVM is been a lackluster stock to watch for months. Did a quick fib retracement anyway and as you can see, there's not much volatility here. BUT upcoming events this week could bring some focus to the stock.
The company develops gene therapies with a primary focus on its lead candidate, ADVM-022. Last week, the company presented data from its 2-Year OPTIC study...
EVFM 's portfolio includes its first FDA-approved product, Phexxi®. The company has presented a series of abstracts all centered around the platform over the last few weeks. In addition, Evofem has also begun advancing its EVO100 platform in treating chlamydia and gonorrhea.
What To Watch With EVFM Stock This Week
This week, Evofem continues its circuit of...
All,
I am already scaled in big here. I am without a doubt this stock will at least double.
***KEEP IN MIND THIS IS AN 8M FLOAT COMPANY
1. Do your own DD you will notice all that has really happened is low float short sellers have just railed the price down
2. This companies price targets are insane not to mention 8M float will make this EXPLODE on any good...
All,
Just look at larger timeframes and price targets + last two EPS. I'm going in with 5% stop loss here. No reason not to. Undervalued, float is mediocre nothing great, but absolutely worth a stab here.
Beyond Air has continued a strong uptrend since June. Recently its bin tapering and has shown a symmetrical triangle formation. A Brake out to the upside is likely to continue the uptrend. Watch for a move past the top of the triangle at 11.88 level for conformation and more possible upside. No resistance till 12.50 a high not seen since March 4, 2020
VRPX is another one of the former penny stock darlings of the year. Big breakout mid August put it on everyone's radars now it's about sustaining this higher price level and subsequent valuation. At today's price of around $20.25, the market cap is 3.5x the size it was just a few weeks ago. Thanks to FDA related headlines, VRPX stock skyrocketed. "The FDA has...
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. Excellent bullish divergence on the monthly. Great time for a long trade on this asset that could attempt a retarget in the $ 240 zone.
FULC news catalyst popped the stock into the previous gap and right back to testing this clear resistance level that was previous support. After plotting the fib retracement is looks like the 50 Fib line is an area that might need to set up as the higher support level if there's any hope of FULC sustaining higher levels. We'll have to see what happens next.
"The...
It's interesting to see what happens after plotting out fib lines sometimes. SAVA , for instance...using the earlier lows and the recent high as anchors we can see that the 382 fib line has been a very clear area of both support and resistance almost to the exact mark. Sure 236 played this role before the Alzheimer's data but now SAVA has reset back to some...
When I say "historic" for BMY I'm not talking ATH but the stock's encroaching on an area that has been tested 3 times being rejected each time. This is the 236 fib area using 2016's high as the top anchor. It's been 5 years since BMY traded well above this area. But with the way attention is being placed on immunotherapy stocks, it could be something to keep in...
NTEC trying to break and hold above this 786 fib level ....AGAIN. It was a previous area of support leading up to the last sell-off but since breaking below it has remained a sticky level of resistance.
"Aside from the cannabis directive, the company has also built a stronger pipeline for things like cancer. In fact, late last month, a patent abstract from...
Had to go way back to find some levels to plot against and 2017 looks like it's the mark. The interesting part is that this 236 area has been an area of traffic in the past. Considering that PAVM failed to break and hold (for now) once again might reinforce that idea. Prior to reaching those highs, the stock tested this area a few more times but failed at every...
